| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
11,447,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
23,616 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.008 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Trias Joaquim |
Sr. VP, Preclinical Developmen |
• – – |
2010-09-21 |
4 |
OE |
$1.51 |
$6,614 |
D/D |
4,380 |
198,546 |
|
- |
|
| Hislop Colin |
Sr. VP, Cardiovasc. Prod. |
• – – |
2010-09-21 |
4 |
OE |
$0.26 |
$3,818 |
I/I |
14,683 |
15,183 |
|
- |
|
| Hislop Colin |
Sr. VP, Cardiovasc. Prod. |
• – – |
2010-08-18 |
4 |
B |
$4.80 |
$2,400 |
I/I |
500 |
500 |
1.91 |
- |
|
| Truex Paul F |
President and CEO |
• • – |
2010-07-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
23,364 |
779,253 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
86,000 |
802,617 |
|
- |
|
| Trias Joaquim |
Sr. VP, Preclinical Developmen |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
194,166 |
|
- |
|
| Odink Debra |
VP, Pharmaceutical R&D |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Lowe Christopher P. |
CFO & VP of Administration |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
57,523 |
|
- |
|
| Kilfoil Georgina |
SVP, Prod. Dev. & Project Mngm |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
22,500 |
|
- |
|
| Lau Stephen |
VP, Corp. & Business Dev. |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,000 |
|
- |
|
| Hislop Colin |
Sr. VP, Cardiovasc. Prod. |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
45,841 |
|
- |
|
| Fritsch Ursula |
VP, Glob. Reg. & Compliance |
• – – |
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
83,615 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2010-04-07 |
4 |
OE |
$0.14 |
$3,271 |
D/D |
23,364 |
716,617 |
|
- |
|
| Henney Christopher S |
Director |
– • – |
2010-04-01 |
4 |
OE |
$0.26 |
$49,473 |
D/D |
40,887 |
102,429 |
|
- |
|
| Lowe Christopher P. |
CFO & VP of Administration |
• – – |
2010-03-31 |
4 |
OE |
$0.14 |
$2,155 |
I/I |
9,637 |
9,637 |
|
- |
|
| Kilfoil Georgina |
SVP, Prod. Dev. & Project Mngm |
• – – |
2010-03-24 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
87,616 |
|
- |
|
| Kilfoil Georgina |
SVP, Prod. Dev. & Project Mngm |
• – – |
2010-03-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
70,093 |
|
- |
|
| Sofinnova Venture Partners Vi L P |
10% Owner |
– – • |
2010-03-04 |
4 |
A |
$6.58 |
$7,839,946 |
D/D |
1,164,662 |
3,983,230 |
|
- |
|
| Sofinnova Venture Partners Vi L P |
10% Owner |
– – • |
2010-03-04 |
4 |
A |
$0.00 |
$4,097,698 |
D/D |
2,818,568 |
2,818,568 |
|
- |
|
| Sofinnova Management Vi, L.l.c. |
10% Owner |
– – • |
2010-03-04 |
4 |
A |
$6.58 |
$8,462,757 |
I/I |
1,253,635 |
4,072,203 |
|
- |
|
| Sofinnova Management Vi, L.l.c. |
10% Owner |
– – • |
2010-03-04 |
4 |
A |
$0.00 |
$4,097,698 |
I/I |
2,818,568 |
2,818,568 |
|
- |
|
| Healy James |
Director |
– • – |
2010-03-04 |
4 |
A |
$6.58 |
$8,462,757 |
I/I |
1,253,635 |
4,092,646 |
|
- |
|
| Healy James |
Director |
– • – |
2010-03-04 |
4 |
A |
$0.00 |
$4,097,698 |
I/I |
2,818,568 |
2,839,011 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2010-03-04 |
4 |
A |
$6.58 |
$12,967,378 |
D/D |
1,921,656 |
20,739 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2010-03-04 |
4 |
A |
$0.00 |
$6,344,222 |
D/D |
4,364,458 |
14,399 |
|
- |
|
221 Records found
|
|
Page 8 of 9 |
|
|
